Bavarian Nordic Enters Clinical Trials With Prostate Cancer Vaccine

Bavarian Nordic's subsidiary, BN ImmunoTherapeutics has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer. A Phase I/II safety and tolerability study in 18 male patients with non-metastatic as well as hormone-insensitive prostate cancer has begun enrolment in the US. Secondary objectives of the trial include examining the ability of the vaccine to induce prostate antigen-specific immune responses, as well as clinical anti-tumour activity. Preliminary data is expected during second half year 2009. The therapeutic vaccine, based on the Company's MVA-BN(R) technology, is designed to generate cellular and humoral immune responses to PSA and PAP (prostate specific antigen and prostatic aci...